Sex-Specific Differences in Antidepressant and Antipsychotic Treatment Outcomes and Serum Levels in Children and Adolescents
Pharmaceutics · 30.07.2025 · 17 (8) · 983
DOI: 10.3390/pharmaceutics17080983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 30.07.2025. Verfasst von Maike Scherf-Clavel und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Wuerzburg, 97080 Wuerzburg, Germany. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Federal Institute for Drugs and Medical Devices, German Federal Ministry of Education and Research, Verein zur Durchführung Neurowissenschaftlicher Tagungen e.V..
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Sex-specific differences in psychopharmacological treatment have gained increasing attention in adults, with studies showing that women often have higher serum concentrations of psychotropic drugs due to biological differences. However, despite recognition of these differences in adults, reference ranges for therapeutic drug monitoring (TDM) in general, but even more sex-specific therapeutic windows for psychotropic drugs, are lacking in children and adolescents, who may metabolize and respond to medications differently.
Aim
The study aimed to investigate sex-specific differences in antidepressant (AD) and antipsychotic (AP) -treatment outcomes, and pharmacokinetics in childhood/adolescence. In particular, we examined differences in AD and AP serum levels and clinical effects, including adverse drug effects (ADEs) and therapeutic effectiveness.
Methods
This study is part of the multicenter “TDM-VIGIL” pharmacovigilance project, which prospectively followed patients aged 6–18 years treated with AD and AP across 18 child psychiatric centers in German-speaking countries from 2014 to 2018. Clinical data, including drug concentrations (AD: fluoxetine, mirtazapine, (es)citalopram, sertraline; AP: aripiprazole, quetiapine, olanzapine, risperidone), were collected using an internet-based registry, and treatment outcomes and ADEs were assessed during routine visits. Statistical analyses were performed to examine sex differences in pharmacokinetics and clinical responses, adjusting for age, weight, and other confounders.
Results
A total of 705 patients (66.5% girls, 24.7%
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Wuerzburg, 97080 Wuerzburg, Germany.
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital Wuerzburg, 97080 Wuerzburg, Germany.
- Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, 13353 Berlin, Germany.
- The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY 11004, USA.
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY 11549, USA.
- Department of Child and Adolescent Psychiatry/Psychotherapy, University Hospital Ulm, 89075 Ulm, Germany.
ORCID-Profile: Maike Scherf-Clavel, Stefanie Fekete, Christoph U Correll, Andreas Karwautz, Wolfgang Briegel, Michael Kaess, Michael Kölch, Tobias J Renner, Susanne Walitza, Franca Keicher, Sebastian Walther, Marcel Romanos, Karin M Egberts, Regina Taurines
Förderung
- German Federal Institute for Drugs and Medical Devices
- German Federal Ministry of Education and Research
- Verein zur Durchführung Neurowissenschaftlicher Tagungen e.V.
Zitieren
APA
Scherf-Clavel, M., Fekete, S., Gerlach, M., Correll, C. U., Plener, P., Fegert, J. M., Karwautz, A., Heuschmann, P., Banaschewski, T., Briegel, W., Fleischhaker, C., Hellenschmidt, T., Imgart, H., Kaess, M., Kölch, M., Reitzle, K., Renner, T. J., Rexroth, C., Schulte-Körne, G., …, & Taurines, R. (2025). Sex-Specific Differences in Antidepressant and Antipsychotic Treatment Outcomes and Serum Levels in Children and Adolescents. Pharmaceutics, 17(8), 983. https://doi.org/10.3390/pharmaceutics17080983
Vancouver
Scherf-Clavel M, Fekete S, Gerlach M, Correll CU, Plener P, Fegert JM, et al. Sex-Specific Differences in Antidepressant and Antipsychotic Treatment Outcomes and Serum Levels in Children and Adolescents. Pharmaceutics. 2025;17(8):983. doi:10.3390/pharmaceutics17080983
BibTeX
@article{ScherfClavel2025,
author = {Scherf-Clavel, Maike and Fekete, Stefanie and Gerlach, Manfred and Correll, Christoph U and Plener, Paul and Fegert, Jörg M and Karwautz, Andreas and Heuschmann, Peter and Banaschewski, Tobias and Briegel, Wolfgang and Fleischhaker, Christian and Hellenschmidt, Tobias and Imgart, Hartmut and Kaess, Michael and Kölch, Michael and Reitzle, Karl and Renner, Tobias J and Rexroth, Christian and Schulte-Körne, Gerd and Theisen, Frank and Walitza, Susanne and Wewetzer, Christoph and Keicher, Franca and Unterecker, Stefan and Walther, Sebastian and Romanos, Marcel and Egberts, Karin M and Vloet, Timo and Taurines, Regina},
title = {Sex-Specific Differences in Antidepressant and Antipsychotic Treatment Outcomes and Serum Levels in Children and Adolescents},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {8},
pages = {983},
doi = {10.3390/pharmaceutics17080983}
}
EUVIMED